Literature DB >> 9818940

Protein modification by the lipid peroxidation product 4-hydroxynonenal in the spinal cords of amyotrophic lateral sclerosis patients.

W A Pedersen1, W Fu, J N Keller, W R Markesbery, S Appel, R G Smith, E Kasarskis, M P Mattson.   

Abstract

We report increased modification of proteins by 4-hydroxynonenal (HNE), a product of membrane lipid peroxidation, in the lumbar spinal cord of sporadic amyotrophic lateral sclerosis (ALS) patients versus that of neurologically normal controls. By immunohistochemistry, HNE-protein modification was detected in ventral horn motor neurons, and immunoprecipitation analysis revealed that one of the proteins modified by HNE was the astrocytic glutamate transporter EAAT2. Given that the function of proteins modified by HNE can be severely compromised as previously demonstrated for glutamate transporters in cortical synaptosome preparations, our findings suggest a scenario in which oxidative stress leads to the production of HNE, impairment of glutamate transport, and excitotoxic motor neuron degeneration in ALS.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9818940     DOI: 10.1002/ana.410440518

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  75 in total

1.  S100B protein and 4-hydroxynonenal in the spinal cord of wobbler mice.

Authors:  Valentina Corvino; Rita Businaro; Maria Concetta Geloso; Paolo Bigini; Valentina Cavallo; Elena Pompili; Tiziana Mennini; Lorenzo Fumagalli; Fabrizio Michetti
Journal:  Neurochem Res       Date:  2003-02       Impact factor: 3.996

2.  Naturally occurring genetic variability in expression of Gsta4 is associated with differential survival of axotomized rat motoneurons.

Authors:  Mikael Ström; Faiez Al Nimer; Rickard Lindblom; Jens Randel Nyengaard; Fredrik Piehl
Journal:  Neuromolecular Med       Date:  2011-12-08       Impact factor: 3.843

Review 3.  Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders.

Authors:  Mark P Mattson
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

4.  Restricted expression of G86R Cu/Zn superoxide dismutase in astrocytes results in astrocytosis but does not cause motoneuron degeneration.

Authors:  Y H Gong; A S Parsadanian; A Andreeva; W D Snider; J L Elliott
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

Review 5.  Stem cell-derived motor neurons: applications and challenges in amyotrophic lateral sclerosis.

Authors:  Jason R Thonhoff; Luis Ojeda; Ping Wu
Journal:  Curr Stem Cell Res Ther       Date:  2009-09       Impact factor: 3.828

6.  Neuronal glucose metabolism is impaired while astrocytic TCA cycling is unaffected at symptomatic stages in the hSOD1G93A mouse model of amyotrophic lateral sclerosis.

Authors:  Tesfaye W Tefera; Karin Borges
Journal:  J Cereb Blood Flow Metab       Date:  2018-03-19       Impact factor: 6.200

Review 7.  TDP-43/FUS in motor neuron disease: Complexity and challenges.

Authors:  Erika N Guerrero; Haibo Wang; Joy Mitra; Pavana M Hegde; Sara E Stowell; Nicole F Liachko; Brian C Kraemer; Ralph M Garruto; K S Rao; Muralidhar L Hegde
Journal:  Prog Neurobiol       Date:  2016-09-28       Impact factor: 11.685

8.  Nitric oxide signaling is disrupted in the yeast model for Batten disease.

Authors:  Nuno S Osório; Agostinho Carvalho; Agostinho J Almeida; Sérgio Padilla-Lopez; Cecília Leão; João Laranjinha; Paula Ludovico; David A Pearce; Fernando Rodrigues
Journal:  Mol Biol Cell       Date:  2007-05-02       Impact factor: 4.138

Review 9.  Modulation of brain hemichannels and gap junction channels by pro-inflammatory agents and their possible role in neurodegeneration.

Authors:  Juan A Orellana; Pablo J Sáez; Kenji F Shoji; Kurt A Schalper; Nicolás Palacios-Prado; Victoria Velarde; Christian Giaume; Michael V L Bennett; Juan C Sáez
Journal:  Antioxid Redox Signal       Date:  2009-02       Impact factor: 8.401

Review 10.  Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers.

Authors:  Paul C Trippier; Kristin Jansen Labby; Dustin D Hawker; Jan J Mataka; Richard B Silverman
Journal:  J Med Chem       Date:  2013-03-27       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.